By Counterforce Health Team in Naglazyme (galsulfase) —

Renewing Naglazyme (Galsulfase) Coverage with Humana in Ohio: 2025 Requirements and Timeline

Answer Box: Renewing Naglazyme Coverage with Humana

Naglazyme (galsulfase) requires prior authorization renewal every 6-12 months with Humana in Ohio. Start your renewal 30 days before expiration to avoid therapy interruption. Submit updated clinical documentation showing ongoing benefit through Humana's provider portal or fax to 1-877-486-2621. If denied, you have 65 days to appeal and can request expedited review (72-hour decision) for urgent cases by calling 877-856-5702. Ohio residents also have external review rights through the Ohio Department of Insurance if internal appeals fail.

Table of Contents

  1. Renewal Triggers: When to Start
  2. Evidence Update: What's Changed Since Last Approval
  3. Renewal Packet: Required Documentation
  4. Timeline: Submission to Decision
  5. If Coverage Lapses: Bridge Options
  6. Annual Changes: What to Re-verify
  7. Appeals Process for Denials
  8. Personal Tracker Template

Renewal Triggers: When to Start

Your Naglazyme prior authorization doesn't automatically renew. Start the process 30 days before your current approval expires to ensure continuous coverage. Common renewal triggers include:

  • Expiration notice from Humana (typically mailed 60 days before expiration)
  • Pharmacy rejection when trying to fill your prescription
  • Provider notification from your infusion center about upcoming authorization end
Tip: Check your approval letter for the exact expiration date. Humana typically approves Naglazyme for 6-12 month periods, requiring documentation of ongoing medical necessity for renewal.

Red flags that suggest starting early:

  • Previous denials or delays with this medication
  • Recent changes to your Humana plan or formulary
  • New medical conditions or medication changes
  • Gaps in treatment or monitoring

Evidence Update: What's Changed Since Last Approval

Humana requires proof that Naglazyme continues to provide clinical benefit. Your renewal must demonstrate:

Response to Therapy

Document measurable improvements or stabilization since starting treatment:

  • 6-Minute Walk Test (6MWT) results showing maintained or improved walking distance
  • 3-Minute Stair Climb Test scores demonstrating functional capacity
  • Pain scores and mobility assessments
  • Pulmonary function tests if respiratory symptoms are present

Adherence Documentation

Provide evidence of consistent treatment:

  • Infusion center records showing regular weekly infusions
  • Pharmacy refill history demonstrating no missed doses
  • Provider attestation confirming patient compliance

Safety Monitoring

Include recent assessments showing therapy is well-tolerated:

  • Liver function tests within the past 6 months
  • Cardiac evaluation if indicated by MPS VI progression
  • Infusion reaction documentation and management protocols

Renewal Packet: Required Documentation

Core Requirements for Humana Renewal

Document Type Specific Requirements Where to Obtain
Prior Authorization Form Humana-specific PA form, signed by prescriber Humana Provider Portal
Medical Necessity Letter Updated clinical justification with current status Treating physician
Diagnosis Confirmation ICD-10 code E76.29 (MPS VI) with supporting enzyme assay or genetic testing Medical records
Functional Assessments 6MWT, stair climb tests, PODCI scores from past 6 months Infusion center or clinic
Treatment History Documentation of all infusions since last approval Pharmacy and infusion records
Monitoring Results Recent labs, cardiac/pulmonary assessments as indicated Hospital or clinic

Medical Necessity Letter Structure

Your prescriber's letter should include:

  1. Patient identification and confirmed MPS VI diagnosis
  2. Current clinical status with objective measures
  3. Response to Naglazyme since initiation or last renewal
  4. Continued medical necessity based on ongoing symptoms and functional limitations
  5. Lack of alternatives (no substitute therapies exist for MPS VI)
  6. Dosing rationale (1 mg/kg IV weekly per FDA labeling)
Clinician Corner: Reference the FDA prescribing information and BioMarin's clinical data when documenting ongoing need. Include specific functional improvements or prevention of deterioration.

Timeline: Submission to Decision

Standard Processing Times

  • Humana review period: 30 days for pre-service medical decisions
  • Expedited review: 72 hours if delay would jeopardize health
  • Part D drug appeals: 7 days standard response time

Submission Methods

Online: Humana Provider Portal (fastest) Fax: 1-877-486-2621 (confirm current number) Mail: Address provided on PA form (varies by plan type)

Note: Keep copies of all submissions and request confirmation of receipt. Humana must notify you of their decision within the timeframes above.

If Coverage Lapses: Bridge Options

If your renewal is denied or delayed, immediate action is critical. Interrupting Naglazyme therapy can lead to functional decline in MPS VI patients.

Emergency Access Options

  1. BioMarin RareConnections: Contact the manufacturer's patient support program for emergency supply assistance
  2. Hospital administration: Some facilities can provide doses from stock during urgent situations
  3. Insurance emergency override: Request temporary coverage while appeals are processed
  4. Expedited appeal: Call Humana at 877-856-5702 to request 72-hour review for urgent cases

Documentation for Bridge Coverage

  • Clinical urgency letter from your physician explaining risks of interruption
  • Previous approval history showing established therapy
  • Current medical necessity demonstrating ongoing need

When therapy is interrupted for 6+ months, Humana typically requires reauthorization with enhanced monitoring for the first few re-initiation infusions.

Annual Changes: What to Re-verify

Humana's formulary and coverage policies can change annually. Before January 1st each year:

Check Your Plan's 2025 Updates

  • Formulary status: Verify Naglazyme remains covered
  • Tier placement: Confirm cost-sharing requirements
  • Prior authorization requirements: Review any new restrictions
  • Preferred sites of care: Check if infusion location requirements changed

Common Changes That Affect Renewals

  • New step therapy requirements (though unlikely for orphan drugs like Naglazyme)
  • Enhanced documentation standards for high-cost biologics
  • Site-of-care restrictions (hospital vs. infusion center requirements)
  • Quantity or frequency limits based on updated policies

From our advocates: "One family discovered their Humana plan moved Naglazyme to a higher tier in 2024, tripling their copay. They successfully appealed using medical necessity documentation and obtained a formulary exception that maintained their previous cost-sharing level throughout the year."

Appeals Process for Denials

If your renewal is denied, Ohio residents have strong appeal rights:

Internal Appeals with Humana

  • Timeline: 65 days from denial notice to file appeal
  • Contact: 877-856-5702 (TTY: 711)
  • Documentation: Include all clinical evidence supporting continued need
  • Response time: 7 days for Part D drugs, 30 days for medical services

Expedited Appeals

Request expedited review if:

  • Standard timeline would "seriously jeopardize your health"
  • You're currently on therapy and at risk of interruption
  • Your physician certifies urgent medical need

Ohio External Review

If Humana upholds the denial:

  • Timeline: 180 days from final internal denial
  • Process: File with your health plan, which notifies Ohio Department of Insurance
  • Review: Independent medical experts evaluate your case
  • Decision: Binding on Humana if overturned

Ohio Department of Insurance Consumer Hotline: 1-800-686-1526

Personal Tracker Template

Use this template to monitor your renewal process:

Current Authorization:

  • Approval start date: ___________
  • Expiration date: ___________
  • Approved dose/frequency: ___________

Renewal Timeline:

  • Start renewal process (30 days before expiration): ___________
  • Documents submitted: ___________
  • Humana decision received: ___________
  • Next renewal due: ___________

Key Contacts:

  • Prescribing physician: ___________
  • Infusion center coordinator: ___________
  • Humana member services: ___________
  • BioMarin RareConnections: ___________

Frequently Asked Questions

How long does Humana take to approve Naglazyme renewals? Standard review takes up to 30 days, but expedited review is available within 72 hours if medically urgent.

What if Naglazyme becomes non-formulary? You can request a formulary exception with medical necessity documentation. Ohio residents also have external review rights.

Can I request expedited renewal if my current approval is expiring? Yes, if continuing therapy without interruption is medically necessary, you can request expedited processing.

Does step therapy apply to Naglazyme renewals? Unlikely, as no alternative treatments exist for MPS VI, but check your specific plan's requirements.

What happens if I miss infusions during the renewal process? Document any missed doses and their impact. This information supports the urgency of approval and may help with expedited processing.

Counterforce Health helps patients and providers navigate complex prior authorization requirements for specialty medications like Naglazyme. Our platform analyzes denial letters, identifies the specific approval criteria, and generates evidence-backed appeals tailored to each payer's requirements. By streamlining the documentation process and ensuring all necessary clinical evidence is included, we help reduce delays and improve approval rates for life-sustaining therapies. Visit www.counterforcehealth.org to learn more about our prior authorization and appeals support services.

Sources & Further Reading

This information is for educational purposes only and does not constitute medical advice. Always consult with your healthcare provider and insurance plan for specific coverage decisions. For personalized assistance with prior authorization and appeals in Ohio, contact the Ohio Department of Insurance at 1-800-686-1526.

Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.